# Xanthohumol (Chalcone)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/xanthohumol
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 6 / 10
**Category:** Compound
**Also Known As:** (E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one, XN, Hop chalcone, Prenylated chalcone, Humulus chalcone, Beer flavonoid

## Overview

Xanthohumol is a prenylated chalcone flavonoid found primarily in hops that exhibits potent anti-cancer and [neuroprotective](/ingredients/condition/cognitive) properties. It works by activating the Nrf2 [antioxidant](/ingredients/condition/antioxidant) pathway and directly inhibiting cancer cell proliferation with IC50 values of 2.6-4.1 μM in colon cancer cells.

## Health Benefits

• Anti-cancer properties: Demonstrated cytotoxic activity against human cancer cell lines including colon (IC50 2.6-4.1 μM), breast, and prostate cells in preclinical studies
• [Neuroprotective effect](/ingredients/condition/cognitive)s: Activates Nrf2 transcription factor to protect neuronal cells against oxidative stress damage (demonstrated in rat cell lines)
• Anti-malarial activity: Shows inhibitory effects against malaria parasites with IC50 values of 8.2-24.0 μM in laboratory studies
• Oxidative stress reduction: Promotes [reactive oxygen species](/ingredients/condition/antioxidant) regulation through ERK1/2 pathway modulation in lung cancer cells
• Cell proliferation inhibition: Significantly reduces cancer cell proliferation through apoptosis induction in multiple cell line studies

## Mechanism of Action

Xanthohumol activates the Nrf2 transcription factor, which upregulates antioxidant enzymes like [glutathione](/ingredients/condition/detox) S-transferase and NAD(P)H quinone oxidoreductase to protect against [oxidative stress](/ingredients/condition/antioxidant). It also inhibits cancer cell growth by interfering with cell cycle progression and inducing apoptosis through multiple pathways including [NF-κB](/ingredients/condition/inflammation) suppression.

## Clinical Summary

Current evidence for xanthohumol comes primarily from in vitro preclinical studies using human cancer cell lines. Studies show cytotoxic activity against colon cancer cells with IC50 values of 2.6-4.1 μM, along with similar effects in breast and prostate cancer models. Human clinical trials are limited, with most research focusing on cellular and animal models to establish safety profiles and bioavailability. The evidence base remains in early stages with no large-scale human efficacy studies completed.

## Nutritional Profile

Xanthohumol is a prenylated chalcone (C₂₁H₂₂O₅, MW 354.4 g/mol) and is not a nutritional macronutrient source. It is a specialized bioactive polyphenolic compound found primarily in the female inflorescences (strobiles) of hops (Humulus lupulus L.). Key profile details: • Primary source concentration: Hops contain approximately 0.1–1.0% xanthohumol by dry weight, making it the most abundant prenylated flavonoid in hops. • Beer content: Conventional beers contain only ~0.002–0.628 mg/L due to thermal isomerization during brewing (most xanthohumol converts to isoxanthohumol during wort boiling, with conversion rates of ~80–90%). Xanthohumol-enriched beers have been developed containing up to ~10 mg/L. • Dietary supplement forms: Typically available in hop extract capsules providing 5–50 mg per dose, often standardized to ≥1–5% xanthohumol content. • Bioactive compound class: Prenylated chalcone (open-ring flavonoid precursor); characterized by a 2',4',6',4-tetrahydroxy-3'-prenylchalcone structure with a prenyl (3-methylbut-2-enyl) side chain critical for biological activity. • Lipophilicity: LogP ~4.26, indicating high lipophilicity; poorly water-soluble (~1.3 mg/L in water at 25°C). • Bioavailability: Oral bioavailability is low, estimated at approximately 11–33% in rodent models. Absorbed primarily in the small intestine; undergoes extensive first-pass hepatic [metabolism](/ingredients/condition/weight-management) via phase I (CYP450-mediated oxidation and demethylation) and phase II conjugation (glucuronidation and sulfation). Gut microbiota convert xanthohumol to 8-prenylnaringenin (a potent phytoestrogen) and other metabolites. Plasma Cmax following oral dosing in humans (~20 mg) is approximately 0.02–0.15 μM, with Tmax of ~1–4 hours and elimination half-life of ~18–20 hours. • Key functional groups contributing to bioactivity: α,β-unsaturated carbonyl (Michael acceptor enabling Nrf2/Keap1 electrophilic modification), prenyl group (enhancing membrane interaction and potency over non-prenylated analogs by 5–10 fold), and multiple hydroxyl groups ([antioxidant](/ingredients/condition/antioxidant) radical scavenging, ORAC value significantly higher than many conventional flavonoids). • No significant vitamin or mineral content as an isolated compound. • Encapsulation strategies (cyclodextrin inclusion complexes, liposomal formulations, solid lipid nanoparticles) have been shown to improve aqueous solubility by 5–40 fold and oral bioavailability by 2–10 fold in preclinical models.

## Dosage & Preparation

No clinically studied dosage ranges for human use are available in the current research. The existing data are limited to in vitro concentrations (micromolar ranges) which cannot be translated to human dosing recommendations. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Xanthohumol appears well-tolerated in preclinical studies with no major acute toxicity reported at tested concentrations. However, comprehensive human safety data is limited due to lack of extensive clinical trials. Potential interactions with cytochrome P450 enzymes may affect [metabolism](/ingredients/condition/weight-management) of certain medications, though specific drug interactions have not been thoroughly studied. Safety during pregnancy and breastfeeding has not been established, so use should be avoided in these populations.

## Scientific Research

The available research consists primarily of in vitro and preclinical studies demonstrating anti-cancer and [neuroprotective effect](/ingredients/condition/cognitive)s. No human clinical trials, randomized controlled trials, or meta-analyses with PubMed PMIDs were identified in the current literature review.

## Historical & Cultural Context

No information regarding traditional or historical medicinal use of xanthohumol was found in the available research. Its presence in hops suggests potential indirect consumption through beer brewing traditions.

## Synergistic Combinations

Other hop compounds, Nrf2 activators, polyphenols, resveratrol, quercetin

## Frequently Asked Questions

### What is the effective dosage of xanthohumol for cancer prevention?

Effective dosages have not been established in humans since most studies are preclinical. In vitro studies show anti-cancer effects at concentrations of 2.6-4.1 μM, but human bioavailability and optimal dosing require further clinical research.

### Can xanthohumol cross the blood-brain barrier for neuroprotection?

Xanthohumol's ability to cross the blood-brain barrier in humans is not well-established. While it shows neuroprotective effects through Nrf2 activation in cell studies, brain bioavailability and therapeutic levels in neural tissue need clinical validation.

### Is xanthohumol only found in beer or other sources too?

Xanthohumol is found primarily in hops (Humulus lupulus), with the highest concentrations in hop cones before brewing. Beer contains much lower levels due to processing, while concentrated hop extracts and supplements provide higher amounts.

### Does xanthohumol interact with chemotherapy drugs?

Specific interactions between xanthohumol and chemotherapy agents have not been thoroughly studied in humans. Given its effects on cellular pathways and potential cytochrome P450 interactions, patients undergoing cancer treatment should consult oncologists before use.

### How long does xanthohumol stay active in the body?

Human pharmacokinetic data for xanthohumol is limited, with most studies focusing on in vitro stability. The compound's bioavailability, metabolism rate, and duration of action in humans require further clinical investigation to establish reliable pharmacokinetic profiles.

### What is the difference between xanthohumol and other hop-derived compounds?

Xanthohumol is a chalcone-type flavonoid unique to hops, distinct from other hop compounds like humulone and lupuline which are primarily bittering agents and essential oils. While those compounds contribute to beer's flavor profile, xanthohumol is the bioactive form most studied for anti-cancer and neuroprotective effects. Xanthohumol's chalcone structure specifically enables it to activate the Nrf2 antioxidant pathway, a mechanism less prominent in other hop constituents.

### Is xanthohumol safe for long-term supplementation?

Current preclinical and limited clinical data suggest xanthohumol has a favorable safety profile with no reported serious adverse effects at studied doses, though long-term safety data in humans remains limited. Most toxicity studies have been conducted in cell cultures and animal models rather than extended human trials. Anyone considering long-term supplementation should consult a healthcare provider, particularly those with existing medical conditions or concurrent medications.

### How does xanthohumol's anti-malarial activity compare to its other health effects?

Xanthohumol demonstrates inhibitory effects against malaria parasites in laboratory studies, though this mechanism is less clinically developed than its anti-cancer and neuroprotective properties. The anti-malarial activity appears to operate through different pathways than its Nrf2-activating neuroprotection, suggesting xanthohumol may have multiple therapeutic targets. Currently, anti-cancer and oxidative stress applications are more extensively researched than its potential antimicrobial uses.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*